DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition

By LabMedica International staff writers
Posted on 08 Feb 2017

Image: The DRG:HYBRiD-XL random access analyzer (Photo courtesy of DRG).

The DRG Group, a leading medical diagnostic and laboratory equipment supplier, demonstrated its fully automated random access analyzer, DRG:HYBRiD-XL, along with its newest ELISAs, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

The DRG:HYBRiD-XL is a fully automated, continuous access analyzer that allows the simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests in one sample. It allows medical practitioners to carry out up to 40 tests of different types or 40 times of the same test, or up to 20-patient samples over a wide range of pre-packaged tests to serve different specialties.

DRG also highlighted its newest ELISAs such as Salivary Progesterone HS (High Sensitivity) ELISA, DHT-optimized and Hepcidin 25 (bioactive) HS ELISA kit at MEDLAB 2017. The company’s saliva diagnostics products offer several benefits such as non-invasive sampling, measurement of the free (unbounded) fraction of steroids, and much higher diagnostic relevance with reproducible and reliable results, compared to serum analytics. DRG’s new Salivary Progesterone HS ELISA is calibrated against mass spectrometry, which is considered as gold standard in saliva diagnostics.

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Automatic Hematology Analyzer

CF9600

Thyroid Test

Anti-Thyroid EIA Test

Urine Analyzer

respons® UDS100

Latest MEDLAB 2017 News

Channels

Clinical Chemistry

view channel

Noninvasive Earwax Test Aims to Detect Meniere’s Disease

Meniere’s disease is a chronic inner ear disorder that can cause vertigo, hearing loss, tinnitus, and a feeling of fullness in the ear. Diagnosis can be difficult because symptoms overlap with other vestibular... Read more

Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel

Genetic Testing Identifies Inherited Predisposition in Children With Acute Leukemia

Childhood acute leukemia can involve inherited cancer predisposition that is not always apparent at diagnosis. Previous studies estimate that 4% to 10% of children with hematological malignancies carry... Read more

Single Assay Enables Simultaneous Newborn Screening for Three Severe Genetic Disorders

Newborn screening aims to identify serious genetic disorders within the first days of life, when swift intervention can help prevent irreversible harm. Spinal muscular atrophy, severe combined immunodeficiency,... Read more

Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time

Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. With more than 100 recognized tumor... Read more

New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity

Precise molecular monitoring is central to managing hematologic malignancies, but traditional PCR workflows can limit sensitivity, multiplexing, and result clarity. Limited sample volumes and fragmented... Read more

Hematology

view channel

Immunology

view channel

Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants

Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more

New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening

Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more

Image: The testing approach is designed for people with HIV whose viral load rises while taking dolutegravir, aiming to limit the accumulation and spread of drug resistance in resource-limited settings. (Image Credit: Shutterstock)

HIV Monitoring Strategy Uses Drug Levels to Guide Resistance Testing

HIV viral load can rise during antiretroviral therapy for reasons that do not necessarily indicate drug resistance. Clinicians must distinguish between treatment nonadherence and resistance before deciding... Read more

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

$Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)$

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Pathology

view channel

Image: longer and is more labor-intensive. The approach images fresh, unprocessed tissue in under a minute, avoiding the slower, labor-intensive staining required in conventional pathology (Image Credit: Adobe Stock)

New AI Model Maps Where Glioblastoma Could Return After Surgery

Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more

Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts

Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read more

$Image: Vaginal and urine samples showing endometrial cancer (true positive case; upper row) and no malignant cells (true negative case; lower row). (Jones ER, Narine N, O\'Flynn H, et al. The Lancet Obstetrics, Gynaecology, & Women\'s Health (2026). DOI:10.1016/S3050-5038(26)00222-0.)$

See LabMedica in...

LabMedica

DRG Group Presents New Analyzer and ELISAs at Dubai Lab Exhibition

Latest MEDLAB 2017 News

Channels